It looks like you are visiting from outside the EU. Switch to the US version to see local pricing in USD and local shipping.

Switch to US ($)
Contact +33 (0)3 90 20 54 70
  • Will a single COVID-19 drug be enough to treat all patients?
    Antibody production

    Will a single COVID-19 drug be enough to treat all patients?

    Philippe Funfrock Philippe Funfrock 5 min read

    As more and more biotherapeutics enter the early stages of clinical development, scientists are questioning if current approaches will be sufficient to curb the pandemic. On the one hand, anti-inflammatory…

  1. CAR-T cell therapy

    From the first to the fifth generation of CAR-T cells

    Read more
  2. CAR-T cell therapy

    The structure of CAR-T cells

    Read more
  3. Antibody-drug conjugates

    ADC linkers: Definition and examples

    Read more
  4. Antibody production

    Antibody production: a complete guide

    Read more
  5. Antibody-drug conjugates

    Robust methods for the detailed analysis of drug-to-antibody ratio (DAR) and drug load distribution

    Read more

Let’s talk about science – Scientists in the spotlight

Dr. Louisa James

“The COVID-19 pandemic is helping us bridge the divide between virologists and immunologists”

Read more
Queen Mary University of London (QMUL, UK) Queen Mary University of London (QMUL, UK)
“The COVID-19 pandemic is helping us bridge the divide between virologists and immunologists”
Dr. Mara Freire

Reinventing IgY biotherapeutics

Read more
CICECO, University of Aveiro CICECO, University of Aveiro
Reinventing IgY biotherapeutics
Dr. Melanie Conrad

How the environment shapes immune system development during pregnancy

Read more
Charité Medical University in Berlin Charité Medical University in Berlin
How the environment shapes immune system development during pregnancy
Dr. Mohamed Alfaleh

“Cell-based phage display is helping us isolate more biologically relevant antibodies”

Read more
King Abdulaziz University King Abdulaziz University
“Cell-based phage display is helping us isolate more biologically relevant antibodies”
Prof. Tomáš Kalina

“Researchers are not leveraging the speed and resolution of flow cytometry for clinical evaluation”

Read more
Charles University in Prague Charles University in Prague
“Researchers are not leveraging the speed and resolution of flow cytometry for clinical evaluation”
Prof. Richard Pleass

“Antibodies will make a significant contribution to design effective control strategies for COVID-19”

Read more
LSTM LSTM
“Antibodies will make a significant contribution to design effective control strategies for COVID-19”
Professor Istvan Toth

“Simplicity is the key to successful large-scale applications”

Read more
Queensland University, Australia Queensland University, Australia
“Simplicity is the key to successful large-scale applications”
See More

Read by topic

Cart (0 Items)

Your cart is currently empty.

View Products